Technology

LifeBond is developing a series of next-generation biosurgical products which incorporate a proprietary adhesive platform that mimics the biochemical cross-linking cascade of late stage blood coagulation.  The adhesive formulation forms a network similar to the fibrin network of blood clots but has demonstrated adhesive strength even greater than that of blood-derived fibrin sealants.  LifeBond’s technology functions through the rapid and biocompatible in situ cross-linking of structural proteins.  As they cross-link, proteins in the physiological environment undergo a process of gelation to form an adhesive hydrogel matrix.  The properties of the cross-linking reaction and the hydrogel matrix can be controlled to fit a variety of applications.

Fig: Schematic of the cross-linking that occurs in natural blood clotting and in the curing of fibrin sealants as compared with the cross-linking that occurs in the curing of LifeBond’s adhesive formulation  (McDermott, et al.  Biomacromolecules 2004, 5, 1270-1279)

Intellectual Property

LifeBond has an extensive portfolio of pending patents related to its core technology.  The company’s intellectual property (IP) can be classified into several distinct categories: